Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC By Ogkologos - July 14, 2026 95 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Pregnancy is Safe After Early Breast Cancer in Young Women with... July 17, 2020 Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... December 12, 2019 Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting... August 25, 2020 Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... January 11, 2023 Load more HOT NEWS Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors TRACERx: Using blood tests to track lung cancer EMA Recommends Extension of Indications for Tafasitamab Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia...
